Halyard Health, Inc. (NYSE:HYH) has been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $42.25.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Halyard Health from a “sell” rating to a “buy” rating and set a $44.00 target price on the stock in a research note on Wednesday, May 3rd. TheStreet downgraded shares of Halyard Health from a “b-” rating to a “c” rating in a research note on Wednesday, May 3rd. Deutsche Bank AG raised their target price on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Wednesday, June 28th. Finally, Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/12/halyard-health-inc-hyh-given-average-recommendation-of-buy-by-brokerages.html.

Shares of Halyard Health (NYSE:HYH) traded up 0.10% during midday trading on Friday, hitting $41.31. 274,902 shares of the company were exchanged. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 39.72 and a beta of 1.78. The firm’s 50 day moving average price is $40.17 and its 200 day moving average price is $38.81. Halyard Health has a one year low of $31.59 and a one year high of $43.78.

Halyard Health (NYSE:HYH) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.14. The business had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. Halyard Health’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the firm posted $0.45 earnings per share. Analysts forecast that Halyard Health will post $1.98 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in HYH. CENTRAL TRUST Co increased its stake in shares of Halyard Health by 1.0% in the first quarter. CENTRAL TRUST Co now owns 2,643 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 25 shares in the last quarter. Meadow Creek Investment Management LLC increased its position in Halyard Health by 1.1% in the first quarter. Meadow Creek Investment Management LLC now owns 2,660 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 28 shares during the period. Glen Harbor Capital Management LLC increased its position in Halyard Health by 1.1% in the first quarter. Glen Harbor Capital Management LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 34 shares during the period. Patten Group Inc. increased its position in Halyard Health by 0.4% in the first quarter. Patten Group Inc. now owns 19,629 shares of the medical instruments supplier’s stock valued at $769,000 after buying an additional 75 shares during the period. Finally, Amalgamated Bank increased its position in Halyard Health by 1.2% in the second quarter. Amalgamated Bank now owns 6,655 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 82 shares during the period. 90.28% of the stock is currently owned by institutional investors and hedge funds.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.